Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Regeneron Halts Trial for Antibody Cocktail in Sickest COVID-19 Patients

by Global Biodefense Staff
October 30, 2020
AbCellera and Eli Lilly to Co-Develop COVID-19 Therapeutic Antibodies

Based on the recommendation of the independent data monitoring committee (IDMC), Regeneron Pharmaceuticals has stopped enrolling patients receiving advanced COVID-19 care in clinical trial for its REGN-COV2 antibody cocktail treatment.

Noting “a potential safety signal and an unfavorable risk/benefit profile at this time,” the IDMC recommended severely ill patients requiring high-flow oxygen or mechanical ventilation be placed on hold pending collection and analysis of further data.

The Regeneron trial will continue in outpatients and in hospitalized patients on low or no oxygen, without any recommend trial modifications from the IDMC, suggesting any safety concerns are limited to the sickest participants. Positive, prospective results for this population were announced by the company on Oct. 28 via press release (no data yet published or peer-reviewed). The company stated that in this population, REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits).

Regeneron has shared these results with the U.S. FDA, which is reviewing an Emergency Use Authorization submission for the REGN-COV2 low dose in adults with mild-to-moderate COVID-19 who are at high risk for poor outcomes.

Impact on International Clinical Trials

REGN-COV2 is part of global clinical studies, including the RECOVERY Trial (Randomised Evaluation of COVID-19 Therapy). This UK national clinical trial aims to identify treatments that may be beneficial for people hospitalized with suspected or confirmed COVID-19.

“Since REGN-COV2 is being studied in the RECOVERY trial, we have today discussed this announcement with Regeneron, with the UK Medicines & Healthcare products Regulatory Agency, and with the chair of the RECOVERY independent Data Monitoring Committee,” Professor Peter Horby and Professor Martin Landray, Co-leads, RECOVERY trial, University of Oxford, UK. “The independent Data Monitoring Committee will review the latest data from the ongoing RECOVERY trial on Thursday 5 November. In the meantime, the RECOVERY trial will continue as planned.”

Regeneron was awarded a $450 million contract from the U.S. government in June 2020 to deliver for doses of this antibody cocktail once approved. The company started scaling up manufacturing capacity earlier this year.

Tags: COVID CountermeasuresCOVID-19Editor PickImmune ResponseSARS-CoV-2Therapeutic Antibodies

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy